spacer
home > ebr > summer 2004 > european life sciences
PUBLICATIONS
European Biopharmaceutical Review

European Life Sciences

As the biotech sector continues to mature, its leading companies will deliver more and more products thereby dramatically improving overall sentiment towards the sector. Despite the investor challenges experienced in recent years, over the past 12-18 months we have witnessed a significant and sustained upswing in the US and European markets, as well as in the biotechnology sector in general. On the whole, the prices of quoted companies in both the US and Europe significantly improved over the year to December 2003, with the NASDAQ Biotech Index up more than 50 per cent over the previous 12 months (1). However, since March 2004 there has been a slight correction in both US and European biotech stocks (as shown in Figure 1).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Mark Clement, Chief Executive of Merlin Biosciences

Mark Clement is Chief Executive Officer at Merlin Biosciences. He joined Merlin in March 2000 and serves as Chief Executive. In 1997, he founded MCC Services, a corporate finance consultancy, where he led assignments from nine life sciences companies, including four Fund I investments. In 1992, he co-founded Celsis International plc (a specialist in microbial risk management), where he served as Group Finance Director with responsibility for both finance and European operations. Prior to this, he spent a year at WestLB Panmure as an Associate Director (Corporate Finance). Mark is a Fellow of the Institutes of Chartered Accountants in England and Wales, the Securities Institute and the Insolvency Practitioners Association.

spacer
Mark Clement
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Stability Testing and Forced Degradation Stress Tests - Proactive Risk Management

Whereas the durability of many consumables, have a strong tendency to decrease, stability is and remains a crucial factor for pharmaceuticals. That is why the identification and elimination of factors, which put long-term stability at risk, is central during development – and an important requirement concerning the product’s quality.
More info >>

White Papers

Bio/Pharmaceutical Methods: Do your Analytical Methods Hold Up to Regulatory Scrutiny?

Eurofins BioPharma Product Testing

As FDA guidelines evolve and drug products on the market begin to age, bio/pharmaceutical manufacturers face scrutiny of the original methods used to support these products. Therefore, manufacturers must re-evaluate these methods to ensure they comply with current FDA expectations. Some manufacturers are even facing consent decrees imposed by the agency requiring them to bring methods up to current standards within a specified timeframe. This exercise requires significant amounts of time and resources, which many manufacturers do not have since they are focused on getting their next products to market. For that reason, some clients have been turning to Eurofins Lancaster Laboratories for support.
More info >>

 
Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement